Ashwin R. Sama

608 total citations
26 papers, 460 citations indexed

About

Ashwin R. Sama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Ashwin R. Sama has authored 26 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ashwin R. Sama's work include Genetic factors in colorectal cancer (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ashwin R. Sama is often cited by papers focused on Genetic factors in colorectal cancer (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Ashwin R. Sama collaborates with scholars based in United States, Spain and Taiwan. Ashwin R. Sama's co-authors include Hushan Yang, Bing‐Hua Jiang, Bingshan Li, Ronald E. Myers, Jinliang Xing, Juan Palazzo, Zhong Ye, Jesse Civan, Yinzhi Lai and Terry Hyslop and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Ashwin R. Sama

26 papers receiving 455 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ashwin R. Sama United States 11 309 84 81 80 74 26 460
Yong Mun United States 11 313 1.0× 115 1.4× 50 0.6× 32 0.4× 57 0.8× 43 464
Fa-Chyi Lee United States 9 193 0.6× 156 1.9× 85 1.0× 57 0.7× 50 0.7× 24 385
Hiroki Ikezawa Japan 11 300 1.0× 116 1.4× 95 1.2× 60 0.8× 115 1.6× 32 512
Aliki Taylor United Kingdom 11 385 1.2× 87 1.0× 29 0.4× 112 1.4× 105 1.4× 17 613
Sanjun Cai China 14 345 1.1× 159 1.9× 39 0.5× 143 1.8× 115 1.6× 36 594
Miah Hiang Tay Singapore 11 157 0.5× 207 2.5× 73 0.9× 76 0.9× 59 0.8× 23 437
Cuiling Zhou China 10 253 0.8× 143 1.7× 46 0.6× 48 0.6× 29 0.4× 11 404
Wang‐Zhong Li China 13 275 0.9× 116 1.4× 54 0.7× 71 0.9× 129 1.7× 41 523
Haiqing Ma China 12 145 0.5× 90 1.1× 43 0.5× 150 1.9× 57 0.8× 13 518
Sanjeev Gill Australia 14 354 1.1× 118 1.4× 23 0.3× 33 0.4× 116 1.6× 25 503

Countries citing papers authored by Ashwin R. Sama

Since Specialization
Citations

This map shows the geographic impact of Ashwin R. Sama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwin R. Sama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwin R. Sama more than expected).

Fields of papers citing papers by Ashwin R. Sama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwin R. Sama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwin R. Sama. The network helps show where Ashwin R. Sama may publish in the future.

Co-authorship network of co-authors of Ashwin R. Sama

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwin R. Sama. A scholar is included among the top collaborators of Ashwin R. Sama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwin R. Sama. Ashwin R. Sama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Neely, Jaclyn, Masatoshi Kudo, Richard S. Finn, et al.. (2022). Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial. Cancer Research. 82(12_Supplement). 2145–2145. 12 indexed citations
2.
He, Aiwu Ruth, Roger B. Cohen, Crystal S. Denlinger, et al.. (2019). First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. The Oncologist. 24(9). e930–e942. 54 indexed citations
3.
Hurwitz, Herbert I., Eric Van Cutsem, Johanna C. Bendell, et al.. (2018). Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational New Drugs. 36(4). 683–695. 87 indexed citations
4.
O’Hayer, C. Virginia, Kevin O’Hayer, & Ashwin R. Sama. (2018). Acceptance and Commitment Therapy with Pancreatic Cancer: An Integrative Model of Palliative Care—A Case Report. SHILAP Revista de lepidopterología. 4(1). 1–3. 6 indexed citations
5.
Zhao, Qihong, Anwar Murtaza, Ragini Vuppugalla, et al.. (2018). Abstract 3760: Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade. Cancer Research. 78(13_Supplement). 3760–3760. 8 indexed citations
6.
7.
8.
Lai, Yinzhi, Chun Wang, Jesse Civan, et al.. (2016). Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology. 150(5). 1135–1146. 102 indexed citations
9.
Intenzo, Charles, et al.. (2016). Pancreatic Cancer in Lynch Syndrome: A Case Report. PubMed. 2(1). 36–39. 1 indexed citations
10.
Geethakumari, Praveen Ramakrishnan, et al.. (2016). “The Immune Conundrum”: Acquired Hemophilia A, Immune Thrombocytopenia, and Neutropenia in a Patient with Pancreatic Cancer. PubMed. 2(1). 14–18. 1 indexed citations
11.
Johnson, Jennifer M., Jason Chen, Siraj M. Ali, et al.. (2016). Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome. Journal of Gastrointestinal Cancer. 49(2). 203–206. 6 indexed citations
12.
13.
Williams, Noelle L., Joshua D. Palmer, Voichita Bar‐Ad, et al.. (2015). Hepatoid Carcinoma of the Pancreas: A Case Report and Review of the Literature. PubMed. 1(1). 3–6. 11 indexed citations
14.
O’Hayer, Kevin, John L. Farber, Charles J. Yeo, & Ashwin R. Sama. (2015). HER-2-Positive Ampullary Adenocarcinoma: A Case Report. PubMed. 1(1). 7–10. 3 indexed citations
15.
Yeung, Vincent, Joshua D. Palmer, Noelle L. Williams, et al.. (2015). Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report. PubMed. 1(1). 22–25. 2 indexed citations
16.
Jacobs, Samuel A., James J. Lee, Thomas J. George, et al.. (2015). Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab. Molecular Cancer Therapeutics. 14(12_Supplement_2). C46–C46. 1 indexed citations
17.
Schilder, Russell J. & Ashwin R. Sama. (2014). Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management. International Journal of Women s Health. 6. 149–149. 4 indexed citations
18.
Gonsalves, Wilson I., Tsewang Tashi, Ibrahim Aldoss, et al.. (2011). Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: A veterans' affairs central cancer registry (VACCR) database analysis. Journal of Surgical Oncology. 104(6). 667–671. 25 indexed citations
19.
Thota, Ramya, Tashi Tobgay, Wilson I. Gonsalves, et al.. (2011). Prognostic significance of positive lymph node ratio in resected esophageal cancer.. Journal of Clinical Oncology. 29(4_suppl). 100–100. 1 indexed citations
20.
Davies, Terry F., Wilson I. Gonsalves, Tsewang Tashi, et al.. (2011). Long-standing diabetes and its effects on outcomes in colon cancer.. Journal of Clinical Oncology. 29(15_suppl). e14019–e14019. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong Mun Breakdown of academic impact, for papers by Fa-Chyi Lee Breakdown of academic impact, for papers by Hiroki Ikezawa Breakdown of academic impact, for papers by Aliki Taylor Breakdown of academic impact, for papers by Sanjun Cai Breakdown of academic impact, for papers by Miah Hiang Tay Breakdown of academic impact, for papers by Cuiling Zhou Breakdown of academic impact, for papers by Wang‐Zhong Li Breakdown of academic impact, for papers by Haiqing Ma Breakdown of academic impact, for papers by Sanjeev Gill
Rankless by CCL
2026